Medicus Pharma Ltd.
For the period ended Dec 31, 2025. Filed Mar 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 25, 2026
MDCX$1.89+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Shareholders' Equity
| Supplemental information | |||
|---|---|---|---|
| Cash paid for interest | $221,663 | 40,563 | |
| Supplemental disclosure of non-cash investing and financing activities | |||
| Right-of-use assets obtained in exchange for lease liabilities | $ | - | 356,805 |
| Deemed dividend on warrant inducement | $11,837,298 | - | |
| Issuance costs included in accounts payable | $95,360 | 265,025 | |
| Shares issued for Antev asset acquisition | $2,129,410 | - | |
| Shares to be issued for Antev asset acquisition | $313,934 | - | |
| Issuance of shares related to SEPA agreement | $300,000 | - | |
| Accrued interest converted into common shares | $ | - | 38,462 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.